10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $35M | -$79M | 83.6% | -247.4% | -42.5% | -27.3% | -$86M | $75M | $217M |
| 2024 | $3M | -$37M | 68.8% | -1423.6% | -169.1% | -25.6% | -$131M | $75M | $56M |
| 2023 | $0 | -$101M | — | — | -198.0% | -68.7% | -$97M | $55M | $99M |
| 2022 | $0 | -$94M | — | — | -126.8% | -60.3% | -$77M | $33M | $122M |
| 2021 | $0 | -$89M | — | — | -137.7% | -75.7% | -$72M | $33M | $82M |
| 2020 | $3M | -$62M | 0.0% | -1995.8% | -85.3% | -50.6% | -$60M | $33M | $79M |
| 2019 | $0 | -$53M | — | — | -40.9% | -32.9% | -$48M | $20M | $126M |
| 2018 | $0 | -$33M | — | — | 43.2% | -334.7% | -$25M | $10M | $8M |
| 2017 | — | -$22M | — | — | 49.4% | -27.1% | -$22M | — | $27M |
| 2016 | — | -$23M | — | — | 99.7% | — | -$22M | — | $15M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $9M | -$16M | 81.6% | -186.1% | -10.4% | -6.4% | — | $75M | $195M |
| Mar '26 | $3M | -$20M | 77.9% | -749.9% | -12.0% | -7.5% | — | $75M | $217M |
| Dec '25 | $3M | -$24M | 85.8% | -922.9% | -12.8% | -8.2% | -$16M | $75M | $217M |
| Sep '25 | $2M | -$30M | 80.1% | -1558.6% | -48.4% | -18.2% | -$28M | $75M | $70M |
| Jun '25 | $2M | -$26M | 83.5% | -1329.5% | -648.2% | -24.5% | -$30M | $75M | $39M |
| Mar '25 | $29M | $282000 | 83.6% | -32.8% | 1.2% | 0.2% | -$12M | $75M | $40M |
| Dec '24 | $1M | -$40M | 78.9% | -2490.6% | -179.8% | -27.2% | -$33M | $75M | $56M |
| Sep '24 | $560000 | -$37M | 59.5% | -6160.7% | -61.5% | -20.6% | -$34M | $75M | $97M |
| Jun '24 | $563000 | $91M | 52.4% | 12629.3% | 96.2% | 43.1% | -$30M | $75M | $147M |
| Mar '24 | $0 | -$52M | — | — | -4996.7% | -46.1% | -$34M | $55M | $60M |
| Dec '23 | — | -$19M | — | — | -37.4% | -13.0% | -$28M | $55M | $99M |
| Sep '23 | — | -$2M | — | — | -3.4% | -1.3% | -$21M | $55M | $132M |
| Jun '23 | — | -$56M | — | — | -82.5% | -32.1% | -$21M | $33M | $136M |
| Mar '23 | — | -$24M | — | — | -46.5% | -19.3% | -$27M | $33M | $93M |
| Dec '22 | — | -$29M | — | — | -39.3% | -18.7% | -$19M | $33M | $122M |
| Sep '22 | — | -$22M | — | — | -34.9% | -19.0% | -$19M | $33M | $80M |
| Jun '22 | — | -$21M | — | — | -70.5% | -26.2% | -$19M | $33M | $47M |
| Mar '22 | — | -$22M | — | — | -44.2% | -22.0% | -$20M | $33M | $66M |
| Dec '21 | $0 | -$30M | — | — | -46.9% | -25.8% | -$19M | $33M | $82M |
| Sep '21 | $0 | -$20M | — | — | -29.4% | -16.7% | -$14M | $33M | $76M |
How the market has priced XFOR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, X4 Pharmaceuticals, Inc's revenue has grown 63.6% per year. These are computed facts, not advice.
As of FY2025, X4 Pharmaceuticals, Inc reported $75M of total debt against $217M of cash; operating income covered interest expense -9.8×.
In FY2025, gross margin was 83.6%, operating margin -247.4%, and net margin -225.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.